Humanistic burden of mucopolysaccharidoses: a systematic literature review

被引:3
作者
Li, Joyce Wai-Yin [1 ]
Yan, Kevin [1 ]
Balijepalli, Chakrapani [1 ]
Druyts, Eric [1 ,2 ]
机构
[1] Pharmalyt Grp, Vancouver, BC, Canada
[2] Pharmalyt Grp, 422 Richards St,Suite 170, Vancouver, BC V6B 2Z4, Canada
关键词
Mucopolysaccharidoses; systematic review; humanistic burden; quality-of-life; health-related quality-of-life; ENZYME REPLACEMENT THERAPY; QUALITY-OF-LIFE; MORQUIO; HEALTH; EXPERIENCE; OUTCOMES; ALPHA; VI;
D O I
10.1080/03007995.2024.2316213
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo systematically review the literature and summarize the health-related quality-of-life (HRQoL) of patients undergoing treatment for mucopolysaccharidoses (MPS), a rare, hereditary lysosomal storage disorder.MethodsA systematic review was performed in accordance with PRISMA guidelines to identify research studies that describe the humanistic burden of MPS. A comprehensive literature search was conducted in EMBASE, MEDLINE, and eligible conferences were screened to include applicable abstracts.ResultsOf 870 identified articles, 15 studies reported the HRQoL burden of patients with MPS undergoing or with a history of ERT and/or HSCT. These studies include patients of MPS I (n = 2), MPS II (n = 4), MPS IV (n = 6), MPS VI (n = 1), and subtype not mentioned (n = 2). Although the quality-of-life of MPS patients is influenced by time of diagnosis, pain, cognitive involvement, severity of disease, mobility, dependence, and time of treatment initiation, the HRQoL scores of MPS patients across all the scales were below the median reference population scores across all dimensions. This is seen in comparison to healthy participants but also in comparison to patients with other chronic illnesses. The multi-organ involvement, neurological impairment, pain, and morbidity associated with the condition not only affects activity of daily living but also affects social functioning, emotional status, employment status among adults, and school functioning among children.ConclusionsThis systematic literature review revealed the substantial humanistic burden of individuals affected by MPS as well as caregivers. Significant variation in HRQoL scores was observed, however studies indicate that the quality-of-life of MPS patients is influenced primarily by severity of disease (MPS type and phenotype), and then by time of diagnosis, pain, cognitive involvement, mobility, dependence, and time of treatment initiation. Further studies are needed to assess the global humanistic burden of MPS, particularly in MPS III, VI, VII, and IX subtypes, in adults, and for a longer follow-up period. Considering the vast array of HRQoL assessment tools available and used in this study, researchers should also consider using scales with condition-specific measures to ensure appropriate estimates of effectiveness.
引用
收藏
页码:709 / 722
页数:14
相关论文
共 33 条
  • [1] Impact of two-year elosulfase alfa treatment on patient-reported outcomes in patients with Morquio syndrome type A: Results from an English managed access agreement
    Adam, Jacqueline
    Cleary, Maureen
    Hendriksz, Christian
    Geberhiwot, Tarekegn
    Hughes, Derralynn
    Jones, Simon A.
    Jovanovic, Ana
    Morrison, Alexandra
    Murphy, Elaine
    Vijay, Suresh
    [J]. MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S19 - S19
  • [2] Elosulfase Alfa Treatment in Morquio A Patients in Iran: A Before and After Study
    Alaei, Mohammadreza
    Shakiba, Marjan
    Saneifard, Hedyeh
    Khanbabaee, Ghamartaj
    Khalilian, Mohammadreza
    Mosallanejad, Asieh
    Tajalli, Saleheh
    Lotfi, Mojtaba
    [J]. IRANIAN JOURNAL OF PEDIATRICS, 2021, 31 (06)
  • [3] Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation
    Aldenhoven, Mieke
    van den Broek, Brigitte T. A.
    Wynn, Robert F.
    O'Meara, Anne
    Veys, Paul
    Rovelli, Attilio
    Jones, Simon A.
    Parini, Rossella
    van Hasselt, Peter M.
    Renard, Marleen
    Bordon, Victoria
    de Koning, Tom J.
    Boelens, Jaap Jan
    [J]. BLOOD ADVANCES, 2017, 1 (24) : 2236 - 2242
  • [4] Ali N, 2015, JIMD REP, V20, P87, DOI 10.1007/8904_2014_396
  • [5] Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure
    Boelens, J. J.
    Wynn, R. F.
    O'Meara, A.
    Veys, P.
    Bertrand, Y.
    Souillet, G.
    Wraith, J. E.
    Fischer, A.
    Cavazzana-Calvo, M.
    Sykora, K. W.
    Sedlacek, P.
    Rovelli, A.
    Uiterwaal, C. S. P. M.
    Wulffraat, N.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 40 (03) : 225 - 233
  • [6] Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey
    Brands, Marion M. G.
    Gungor, Deniz
    van den Hout, Johanna M. P.
    Karstens, Francois P. J.
    Oussoren, Esmee
    Plug, Iris
    Boelens, Jaap Jan
    van Hasselt, Peter M.
    Hollak, Carla E. M.
    Mulder, Margot F.
    Gozalbo, Estela Rubio
    Smeitink, Jan A.
    Smit, G. Peter A.
    Wijburg, Frits A.
    Meutgeert, Hanka
    van der Ploeg, Ans T.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2015, 38 (02) : 323 - 331
  • [7] Up to five years experience with 11 mucopolysaccharidosis type VI patients
    Brands, Marion M. M. G.
    Oussoren, Esmee
    Ruijter, George J. G.
    Vollebregt, Audrey A. M.
    van den Hout, Hannerieke M. P.
    Joosten, Koen F. M.
    Hop, Wim C. J.
    Plug, Iris
    van der Ploeg, Ans T.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2013, 109 (01) : 70 - 76
  • [8] Epidemiology of Mucopolysaccharidoses Update
    Celik, Betul
    Tomatsu, Saori C.
    Tomatsu, Shunji
    Khan, Shaukat A.
    [J]. DIAGNOSTICS, 2021, 11 (02)
  • [9] Neuropsychology assessment and outcomes in adult mucopolysaccharidosis - A systematic review as the first step to service development in a large tertiary Lysosomal Storage Disorders centre
    Chen, Cliff
    Methley, Abigail
    Naicker, Ramona
    Rust, Stewart
    Stepien, Karolina M.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02)
  • [10] Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England
    Cleary, Maureen
    Davison, James
    Gould, Rachel
    Geberhiwot, Tarekegn
    Hughes, Derralynn
    Mercer, Jean
    Morrison, Alexandra
    Murphy, Elaine
    Santra, Saikat
    Jarrett, James
    Mukherjee, Swati
    Stepien, Karolina M.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)